doi: 10.1016/j.cell.2015.07.045.
PD-1 Blockers
Affiliations
- PMID: 26317459
- DOI: 10.1016/j.cell.2015.07.045
Item in Clipboard
PD-1 Blockers
Cell.
.
Free article
Abstract
Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.Semin Oncol. 2017 Apr;44(2):132-135. doi: 10.1053/j.seminoncol.2017.06.007. Epub 2017 Jul 13. Semin Oncol. 2017. PMID: 28923211 Review.
-
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Am J Clin Oncol. 2016. PMID: 26558876 Free PMC article. Review.
-
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.Expert Rev Anticancer Ther. 2015;15(9):981-93. doi: 10.1586/14737140.2015.1074862. Epub 2015 Jul 30. Expert Rev Anticancer Ther. 2015. PMID: 26313415 Review.
-
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.PLoS One. 2015 Jun 18;10(6):e0130142. doi: 10.1371/journal.pone.0130142. eCollection 2015. PLoS One. 2015. PMID: 26086854 Free PMC article.
-
Immunotherapy: pembrolizumab-is the writing on the wall for cancer?Nat Rev Clin Oncol. 2015 Jul;12(7):371. doi: 10.1038/nrclinonc.2015.85. Epub 2015 May 12. Nat Rev Clin Oncol. 2015. PMID: 25963092 No abstract available.
Cited by
-
Current state of immune checkpoints therapy for glioblastoma.Heliyon. 2024 Jan 13;10(2):e24729. doi: 10.1016/j.heliyon.2024.e24729. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38298707 Free PMC article. Review.
-
Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma.Cancers (Basel). 2020 Sep 3;12(9):2495. doi: 10.3390/cancers12092495. Cancers (Basel). 2020. PMID: 32899197 Free PMC article. Review.
-
The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling.Front Oncol. 2019 Dec 3;9:1347. doi: 10.3389/fonc.2019.01347. eCollection 2019. Front Oncol. 2019. PMID: 31850228 Free PMC article.
-
The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.Adv Hematol. 2018 Nov 1;2018:2458679. doi: 10.1155/2018/2458679. eCollection 2018. Adv Hematol. 2018. PMID: 30519261 Free PMC article. Review.
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy.J Immunother Cancer. 2019 Aug 26;7(1):223. doi: 10.1186/s40425-019-0693-y. J Immunother Cancer. 2019. PMID: 31446896 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
